Osiris

Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval?

MSCs-mesenchymal-stem-cells-stromal-cells-small

Graft-versus-host disease (GVHD) is counterintuitive In the weeks and months following a transplant, a major concern is the recipient’s immune system rejecting the “foreign” biological material. But in GVHD, the opposite happens: transplanted tissue unleashes a horde of T cells that spark a cascade of inflammation, within 100 days. Typically, GVHD follows a bone marrow …

Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval? Read More »

Overselling stem cells for COVID-19: WSJ article & UMN PR

EM-of-Novel-Coronavirus-SARS-CoV-2-that-causes-COVID-19

Many are  jumping on the bandwagon of trying stem cells for COVID-19 or testing other cellular therapies for the novel coronavirus disease, but there have been problems with either the rationales for the trials themselves or more often with how they portrayed. Sometimes there has even been outright hype. I’ve called this collective trend of …

Overselling stem cells for COVID-19: WSJ article & UMN PR Read More »

Weekend Stem Cell Reads: Naked mole rats, geckos, brain gel, & more

naked-mole-rats

Here are some stem cell reads for the weekend, ranging from media to research articles. TGIF! What are your stem cell or other science weekend reads? Let’s start with how difficult it is to make IPS cells from naked mole rats! Naked Mole Rat Cells Have a Stable Epigenome that Resists iPSC Reprogramming. It takes more than …

Weekend Stem Cell Reads: Naked mole rats, geckos, brain gel, & more Read More »

Stem Cell & Cell Med Industry Briefs

Where do things stand with some players in the for-profit world of stem cell and cellular medicine companies? Here are a few brief news items with quick analysis. Mesoblast is dominating the news of late. Mesoblast reported good news from its Phase II safety trial for its mesenchymal progenitor cell (MPC) product in patients with …

Stem Cell & Cell Med Industry Briefs Read More »

Osiris FDA Letter: Trick or Treat?

Osiris, a cellular therapy biotech, recently received a so-called “untitled letter” from the FDA. The text of the letter seems on the whole negative in my opinion, while the company’s public reaction to the letter on the other hand could be seen paradoxically as rather cheery. What’s going on here? With Halloween coming, one has …

Osiris FDA Letter: Trick or Treat? Read More »

Pete Shuster on His Choice of Best Stem Cell Company: Osiris

Osiris

This is the first in a series of guest posts on what folks believe are the best compliant stem cell companies out there. You can submit a potential guest post on this topic to me until August 30. Editor’s notes: Pete submitted this to me on Sunday, well before today’s big Osiris news. He must …

Pete Shuster on His Choice of Best Stem Cell Company: Osiris Read More »

Osiris success with Diabetic foot ulcers is a giant step

Osiris

Stem cell & cellular medicine biotech, Osiris, reported a major success today with its cell-based treatment of Diabetic foot ulcers. The data are about as good as it gets. The company’s Grafix product for the ulcers was three times more effective than the control. A cross-over phase where those given the control were switched to …

Osiris success with Diabetic foot ulcers is a giant step Read More »

Interview with BioTime CEO Michael West Part 1: a little stem cell history

Michael-West-PhD-CEO-of-BioTime-1-934x10241

It was my pleasure recently to  talk at length with Dr. Michael West, CEO of the Stem Cell Biotech, BioTime (BTX). West has been at the helm of BioTime since 2007 and is a true pioneer in the stem cell field. He founded Geron (GERN) and was a top leader at Advanced Cell Technology (ACT; stock …

Interview with BioTime CEO Michael West Part 1: a little stem cell history Read More »